Important: New Login Process

We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.

  • If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
  • If you log in with a username and password, you will be prompted to set a new password before accessing your account.

Go to the Login Page to get started.

We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.

BioCentury
  • Company Profiles
  • Target Profiles
  • Product Profiles
Explore BCIQ profiles by entering a product name.
BioCentury | Sep 4, 2020
Emerging Company Profile

Lumen growing lean, green biologics with $16M series B and Gates funding

Having wrangled spirulina into making oral biologics, Lumen aims for low cost and high volume
BioCentury | Nov 6, 2018
Distillery Therapeutics

Infectious disease

BioCentury | Mar 22, 2018
Emerging Company Profile

Hatching antibodies

OstriGen’s ostrich antibodies could yield oral therapies for GI tract diseases
BioCentury | Oct 5, 2017
Product R&D

Avidly specific

How AvidBiotics is taking on the microbiome with bactericidal peptides.
BioCentury | Aug 16, 2017
Emerging Company Profile

Aiming horizontal

SciBac uses horizontal gene transfer to engineer therapeutic bacteria
BioCentury | Dec 16, 2016
Company News

Celltrion biosimilar among CHMP recommendations

BioCentury | Oct 31, 2016
Clinical News

Zinplava bezlotoxumab regulatory update

BioCentury | Oct 24, 2016
Company News

FDA approves Zinplava to reduce CDI recurrence

BioCentury | Jul 25, 2016
Clinical News

Bezlotoxumab regulatory update

BioCentury | Jul 21, 2016
Company News

FDA extends Zinplava review, requests more data

Items per page:
1 - 10 of 21